Positive data will underpin GSK plans to file its GLP-1 RA albiglutide in early 2013
This article was originally published in Scrip
Executive Summary
Competition in the glucagon-like peptide 1 receptor agonists (GLP-1 RA) will have stepped up a notch following the announcement by GlaxoSmithKline (GSK) of positive data from the Phase III Harmony 8 study and from the event driven meta-analysis for assessment of cardiovascular safety conducted across the albiglutide clinical programme. Armed with the data, GSK plans to start global regulatory submissions for Syncria (albiglutide) its type 2 diabetes treatment in early 2013.